ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technology, has hailed the publication of a peer-reviewed paper that highlights the potential of the company's Parsortix system in precision oncology, a field that is revolutionising cancer therapy.
The device allows for the harvesting of intact circulating tumour cells (CTCs) from a simple blood sample, providing a critical tool for cancer research, drug development, and clinical oncology.
Appearing in the journal 'Current Issues in Molecular Biology', the research, with contributions from several leading cancer centres worldwide, demonstrates the system's wide utility across various cancer types.
It particularly emphasises the combined analysis of CTCs and ctDNA (cell-free DNA) in a single blood sample, leading to more comprehensive biomarker profiles.
This approach could significantly enhance patient care by improving the detection of actionable genetic variants and aiding in treatment selection, monitoring treatment resistance, and detecting disease relapse.
Karen Miller, ANGLE's chief scientific officer, said: "As the revolution in 'omics' data evolves, the importance of CTCs to extract genomic and phenotypic profiling information is becoming increasingly evident, providing valuable and potentially actionable data that, subject to further study, may be used to guide patient management decisions in a way that is not possible using only ctDNA."